Infectious disease
Since the COVID-19 pandemic, there has been increased interest in developing a universal antiviral that would stop a pandemic in its tracks. Now some companies are in the testing phase for just that.
On Thursday at the White House, President Biden paid tribute to the 1 million American lives lost due to COVID-19.
Jacqueline Shea will take over as the new CEO and announced plans to discontinue its Phase III Innovate trial to prioritize its heterologous booster strategy for COVID-19.
ICER recommended two out of three outpatient treatments for COVID-19 in today’s market, singling out molnupiravir as having inadequate evidence that it is better than symptomatic care.
Current COVID-19 booster shots have a problem: they last only about four months and appear to have limited efficacy in a vaccinated population. Clearly, a more durable approach is needed.
Despite posting its first profitable quarter as a commercial stage company, shares of Novavax plunged 20% in Tuesday trading due to the slower-than-expected rollout of its COVID-19 vaccine.
Moderna is still fending off patent challenges over the lipid nanoparticle delivery system used in its COVID-19 vaccine.
Life Science industries are seeing massive financial fluctuations in how they’re handling the COVID-19 pandemic, but there is some optimism of a recovery by biopharma executives.
Despite having infinitely better global communications, exact figures are hard to come by for COVID-19 fatalities. Here’s a look at that story and more COVID-19 news.
Janssen’s COVID-19 vaccine is now limited to certain individuals ages 18 years and up after the FDA downgraded its emergency use authorization (EUA).
PRESS RELEASES